KALVISTA PHARMACEUTICALS INC (KALV)

KalVista Pharmaceuticals is Now Oversold (KALV)

KalVista Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for KALV

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Notable Thursday Option Activity: SLG, AOSL, KALV

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

KalVista Pharmaceuticals CFO discloses sale of 40,855 shares (NASDAQ:KALV)

The CFO of KalVista Pharmaceuticals sold 40,855 shares for $613,205. There have been a total of 37 insider trades in the last three months.

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals up 16%, prices $160M offering (NASDAQ:KALV)

KalVista Pharmaceuticals (KALV) priced an underwritten public offering of ~7M shares at a price to the public of $15.25 per share and pre-funded warrants to pur

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

KalVista announces proposed public offering of stock and pre-funded warrants (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV) intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in...

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Two Biotech/pharma stocks to watch - STTK, KALV

Despite positive tidings, shares of Shattuck Labs (STTK) and KalVista Pharmaceuticals (KALV) closed lower Tuesday. Is this a buy-the-dip opportunity?

KalVista stock jumps after trial success (NASDAQ:KALV)

KalVista Pharmaceuticals (KALV) stock rose as its oral therapy for hereditary angioedema, sebetralstat, reached its goals in a Phase 3 trial. Read more here.

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Notable Monday Option Activity: KALV, BYND, URI

Commit To Purchase KalVista Pharmaceuticals At $10, Earn 365% Annualized Using Options

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)